Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 ...Middle East

PR Newswire - News
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous...

Hence then, the article about viking therapeutics reports new data from vk2735 obesity program at obesityweek 2024 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 )

Apple Storegoogle play

Last updated :

Also on site :